PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT7504391

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
YUXIN ZHAO	07/17/2022
JAYACHANDRA P. REDDY	07/18/2022
LAUREN MACEACHERN	07/29/2022
EVANS MONYONCHO	07/29/2022
SAMER KAHWAJI	07/27/2022
PETER MUELLER	07/27/2022

RECEIVING PARTY DATA

Name:	CRINETICS PHARMACEUTICALS, INC.
Street Address:	10222 BARNES CANYON ROAD, BUILDING #2
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17673579

CORRESPONDENCE DATA

Fax Number: (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6504939300

patentdocket@wsgr.com, ljayme@wsgr.com Email: WILSON SONSINI GOODRICH & ROSATI **Correspondent Name:**

650 PAGE MILL ROAD Address Line 1:

Address Line 4: PALO ALTO, CALIFORNIA 94304-1050

ATTORNEY DOCKET NUMBER:	48369-730.201
NAME OF SUBMITTER:	LEA R. JAYME
SIGNATURE:	/Lea R. Jayme/
DATE SIGNED:	08/25/2022

Total Attachments: 6

PATENT REEL: 060897 FRAME: 0679

507457499

PATENT REEL: 060897 FRAME: 0680

	PATENT ASSIGNMENT	Docks	et Number 48369-730.201	
The undersigned:	,			
Yuxin ZHAO San Diego, CA (US)	Jayachandra P, REDDY San Diego, CA (US)	Lauren MACEACHERN Halifax, NS (CA)	4. Samer KAHWAJI Halifax, NS (CA)	
5. Evans MONYONCHO Halifax, NS (CA)	6. Peter MUELLER Medfird, MA (US)			

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Crinetics Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 10222 Barnes Canyon Road, Building #2, San Diego, California 92121 (US), (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR

for which application serial number 17/673,579 was filed on February 16, 2022 in the United States Patent and Trademark Office; and

for which a PCT application serial number PCT/US2022/016577 was filed on February 16, 2022 in the United States Receiving Office of the Patent Cooperation Treaty

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

- 2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.
- Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- 6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which



	PATENT ASSIGNMENT	***************************************	Docket Number 48369-730.201	
together constitute one and	the same agreement.		<u> </u>	
IN WITNESS W	HEREOF, said Inventor(s) have executed and de	slivered this instrument (n said Assignee as of the dates wr	iften below:
Date: Taly 17: 2022	Zhe Kan Yuxin ZHAO			
Date:	Jayachandra P. REDDY			
Date:	Lauren MACEACHERN			:
Date:	Samer KAHWAJI			
Date:	Evans MONYONCHO			
Date:	Peter MUELLER			
RECEIVED AND AGREE	ED TO BY ASSIGNEE: CRINETICS PHAI	RMACEUTICALS, IN	IC.	~
Date: \$\frac{123}{2022}	Signature: Name: Garlan Adams Title: General Counsel			
A				

	PATENT ASSIGNMENT	Docket Number	48369-730.201
together constitute one and ti	ne same agreement.		
IN WITNESS WH	EREOF, said inventor(s) have executed and delivered this instrument	to said Assignee as	of the dates written below:
Date:	Yuxin ZHAO		
Date: 07-18-2V_	Jayachandra P. REDDY		
Date:	Lauren MACEACHERN		
Date:	Samer KAHWAJI		
Date:	Evans MONYONCHO		
Date:	Poter MUELLER		
RECEIVED AND AGREED TO BY ASSIGNEE: CRINETICS PHARMACEUTICALS, INC.			
Date \$\frac{\frac{73}{2022}}{2022}	Signature: Name: Garlan Adams Title: General Counsel		

PATENT ASSIGNMENT	Dockei Number 48369-730,201		
together constitute one and the same agreement.			
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument	to said Assignee as of the dates written below:		
Oate:			
Date:			
Daile: Ally 2 And Lauren MACEACHERN			
Date:Sanier KAHWAJI			
Date 25 Ouly 22 Evans MONYONCHO			
Date:Peter MUELLER			
RECEIVED AND AGREED TO BY ASSIGNEE: CRINETICS PHARMACEUTICALS, I	NC.		
Date: 8/23/2027 Signature: Quirlan Adams Name: Gairlan Adams Title: General Counsel			

	PATENT ASSIGNMENT	Docket Number	48369-730,201
together constitute one and the	he same agreement.		
IN WITNESS WH	EREOF, said Inventor(s) have executed and delivered this instrument	to said Assignee as	of the dates written below:
Date:	NZ		
	Yuxin ZHAO		
Date:	Jayachandra P. REDDY		
Date:			
	Lauren MACEACHERN		
	L. L.		
Date: July 27, 2022	Samer KAHWAJI		
Data			
Date:	Evans MONYONCHO		
Date:	Peter MUELLER		
	FERS MUBLICA		
RECEIVED AND AGREE	D TO BY ASSIGNEE: CRINETICS PHARMACEUTICALS,	INC.	
Date: \$\frac{\frac{3}{23} \frac{25}{2622}}{2622}	Signature Name: Garlan Adams Title: General Counsel		

PATENT ASSIGNMENT	Docket Number	48369-730.201
together constitute one and the same agreement.		
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument	to said Assignee as	of the dates written below:
Date:		
Date:Yuxin ZHAO		
Date:		
Date:		
Date:		
Lauren MACEACHERN		
Date:Samer KAHWAJI		
Samer KAHWAJI		
Date:Evans MONYONCHO		
Evalua dispersional		
11/15/10		
Date: 7/27/22 Perer MUELLER		

RECEIVED AND AGREED TO BY ASSIGNEE: CRINETICS PHARMACEUTICALS, I	INC.	
8/2/2-2 Ob.O. Mak		
Date: Name: Garlap Adams		
Title: General Counsel		